Duaklir Genuair

January 17, 2017January 17, 2017

UK Inhaler Group to Present Data on Inhaled Therapies at Upcoming London Conference

Asthma, COPD, News

Key inhaler information, including compliance by patients with asthma and chronic obstructive pulmonary disease (COPD), along with educating patients and healthcare professionals (HCPs), will be one of the highlights of ... Read more

October 30, 2015November 9, 2015

AstraZeneca’s COPD Inhalation Therapy Now Available in Canada

COPD, News

AstraZeneca Canada has announced that DUAKLIR™ GENUAIR®, a treatment system currently available in other countries to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, is now available in Canada and through the Canadian ... Read more

February 11, 2015November 9, 2015

AstraZeneca Acquires Rights To Actavis’ Branded COPD Portfolio in Canada and US

COPD, News

Actavis and AstraZeneca have recently announced signing a new agreement assuring that AstraZeneca will acquire the rights to Actavis’ respiratory portfolio in both Canada and the United States for an upfront payment worth $600 million upon completion, ... Read more

November 28, 2014November 11, 2015

European Union Approves New Chronic Obstructive Pulmonary Disease Drug

COPD, News

AstraZeneca announced that the European Commission granted their lead drug, Duaklir® Genuair®, marketing authorization as a maintenance bronchodilator treatment for adult patients with chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) ... Read more